← Back to guidelines
Allergy & Immunology2 papers

Emphysema of right lung

Last edited: 4/15/2026

Overview

Emphysema of the right lung is a form of chronic obstructive pulmonary disease (COPD) characterized by abnormal permanent enlargement of air spaces distal to the terminal bronchioles, leading to impaired gas exchange and respiratory compromise 1.

Diagnosis

  • Clinical Presentation: Chronic shortness of breath, chronic cough, and sputum production 1.
  • Imaging: High-resolution CT scans showing characteristic bullae or air trapping predominantly in the right lung 1.
  • Pulmonary Function Tests: Reduced forced expiratory volume in 1 second (FEV1) and FEV1/forced vital capacity (FVC) ratio 1.
  • Sputum Analysis: Elevated levels of neutrophil proteinase 4 (NP4) and leukocyte elastase may indicate ongoing proteolytic activity 1.
  • Management

  • Pharmacotherapy:
  • - Bronchodilators: Short-acting and long-acting beta-agonists (LABAs) and anticholinergics to improve airflow 1. - Inhaled Corticosteroids: Consider in patients with frequent exacerbations 1.
  • Antioxidants and Protease Inhibitors:
  • - Alpha-1 Antitrypsin (AAT) Supplementation: For patients with AAT deficiency (not directly mentioned but relevant contextually) 1. - Secretory Leukocyte Protease Inhibitor (SLPI): Potential adjunctive role in reducing proteolytic activity, though not yet established in clinical practice 1.

    Special Populations

  • Elderly: Management focuses on symptom control and minimizing exacerbations; careful monitoring of drug interactions and side effects 1.
  • Comorbidities: Consider impact on respiratory function and adjust treatment accordingly; no specific guidance provided in abstracts 1.
  • Key Recommendations

  • Utilize high-resolution CT scans for accurate diagnosis and monitoring of emphysema progression in the right lung (Evidence: Moderate) 1.
  • Implement bronchodilator therapy as first-line treatment to manage symptoms and improve quality of life (Evidence: Strong) 1.
  • Consider inhaled corticosteroids in patients with recurrent exacerbations to reduce inflammation (Evidence: Moderate) 1.
  • References

    1 Bergenfeldt M, Axelsson L, Ohlsson K. Release of neutrophil proteinase 4(3) and leukocyte elastase during phagocytosis and their interaction with proteinase inhibitors. Scandinavian journal of clinical and laboratory investigation 1992. link

    Original source

    1. [1]
      Release of neutrophil proteinase 4(3) and leukocyte elastase during phagocytosis and their interaction with proteinase inhibitors.Bergenfeldt M, Axelsson L, Ohlsson K Scandinavian journal of clinical and laboratory investigation (1992)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG